Availability of monoclonal antibodies against SARS-CoV-2 in the Czech Republic

Abstract

In the Czech Republic, based on the relevant decisions of the Ministry of Health of the Czech Republic, monoclonal antibodies are available casirivimab-imdevimab and bamlanivimab for the treatment of indicated SARS-CoV-2 positive patients. The products are administered in infusion sites available in most hospitals.

Every doctor can when meeting the patient's indication criteria for a single application of this product order.

Keywords

• monoclonal antibodies
• SARS-CoV-2, casirivimab-imdevimab
• bamlanivimab